BioPharma Resources

Drug Trial Radar · NCT07168434

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

A Double-blind, Randomized, Placebo-controlled, Multicenter Trial Evaluating the Efficacy and Safety of Saccharomyces Boulardii CNCM I-745 in Adult Patients With Non-constipated Irritable Bowel Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

406

Planned (sponsor's estimate)

Start

Oct 22, 2025

Primary completion

Oct 11, 2026

Study completion Oct 11, 2026

Sponsor

Lead sponsor
BiocodexIndustry
Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks. Secondary efficacy objectives are to evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of IBS patients and on global and individual IBS symptoms, using the IBS-SSS, in comparison to placebo at regular intervals over a 3-month treatment period. This research also aims to evaluate the proportion of patients who improved ≥ 50 points on IBS-SSS and the proportion of responders according to the European Medicines Agency (EMA) definition (based on the patient's global assessment of efficacy and on abdominal pain score), after 8 weeks of treatment. Secondary safety objective is to evaluate the safety profile and tolerability of Saccharomyces boulardii CNCM I-745 capsules 500 mg/day in IBS patients in comparison to placebo

Conditions

  • IBS (Irritable Bowel Syndrome)
  • IBS-D (Diarrhea-predominant)
  • IBS, Mixed Symptoms

Interventions

  • Saccharomyces Boulardii 250 MGDrug

    Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day

  • Placebo 250 mgDrug

    Placebo, 250mg, 2 capsules/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global Irritable Bowel Syndrome (IBS) symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.Time frame: From baseline to day 56

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital de Braga

    Braga, Portugal · Recruiting

  • Hospital da Luz

    Lisbon, Portugal · Not yet recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario de León

    León, Spain · Recruiting

  • Hospital Universitario Gregorio Marañon & Centro de Salud Pavones

    Madrid, Spain · Recruiting

  • Hospital Clínico San Carlos

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario La Paz & Hospital Carlos III

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Regional de Málaga

    Málaga, Spain · Not yet recruiting

  • Hospital Universitario Costa del Sol

    Marbella, Spain · Not yet recruiting

  • Hospital Universitario Central de Asturias & Centro de Salud la Lila

    Oviedo, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.